Related Experiment Videos
Phenylacetic acid derivatives as hPPAR agonists.
Conrad Santini1, Gregory D Berger, Wei Han
1Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. conrad_santini@merck.com
Bioorganic & Medicinal Chemistry Letters
|March 27, 2003
Summary
Researchers developed novel human peroxisome proliferator-activated receptor (hPPAR) agonists. These compounds demonstrated in vivo glucose and triglyceride lowering activity in rodents, with compound 7 showing potency comparable to BRL 49653.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Endocrinology
Background:
- Peroxisome proliferator-activated receptors (PPARs) are key regulators of glucose and lipid metabolism.
- Developing potent and selective PPAR agonists is crucial for treating metabolic disorders like type 2 diabetes and dyslipidemia.
Purpose of the Study:
- To design and synthesize a novel series of human PPAR (hPPAR) agonists.
- To evaluate the in vivo glucose and triglyceride-lowering efficacy of the synthesized compounds in insulin-resistant rodent models.
Main Methods:
- Lead optimization starting from a weakly active structure.
- Chemical synthesis involving homologation, oxamination, and conversion to benzisoxazole and benzofuran scaffolds.
- In vivo assessment of glucose and triglyceride levels in insulin-resistant rodents.
Main Results:
- A series of novel hPPAR agonists were successfully developed.
- Compounds 4, 5, 6, and 7 exhibited in vivo glucose and triglyceride lowering effects.
- Compound 7 demonstrated comparable potency to the reference compound BRL 49653 in reducing glucose and triglycerides in insulin-resistant rodents.
Conclusions:
- The developed benzisoxazole and benzofuran derivatives represent promising candidates for hPPAR agonist-based therapies.
- Compound 7 is a potent agent for managing hyperglycemia and hypertriglyceridemia in insulin resistance.
- Further investigation into the therapeutic potential of these novel agonists is warranted.